Antihistaminic drug bromadryl and stimulated platelet aggregation
The H1-receptor antagonist bromadryl dosedependently inhibited stimulated rat platelet aggregationin vitro. Bromadryl was 10 times more effective on the secondary aggregation of thrombin-stimulated platelets compared with its inhibition of ADP-stimulated primary platelet aggregation in plasma. The inhibition of aggregation was accompanied by a dose-dependent inhibition of thrombin-stimulated malondialdehyde formation and thromboxane B2 production. The results indicate that bromadryl may interfere intracellularly with membrane phospholipid peroxidation and the arachidonic acid metabolism of stimulated platelets. Bromadryl, like other cationic amphiphilic drugs, may inhibit stimulated platelet functions by decreasing the stimulus-induced activation of phospholipase A2. Our results support the possible interference of bromadryl with histamine as an intraplatelet messenger responsible for aggregation.
KeywordsArachidonic Acid Platelet Aggregation Arachidonic Acid Metabolism Antihistaminic Drug Secondary Aggregation
- V. Jančinová, M. Petríková and R. Nosáĺ,The antihistaminic drug cimetidine and arachidonic acid metabolism. Agents and Actions, Spec. Conf. Issue, C434–C436 (1992).Google Scholar
- R. Nosáĺ, V. Jančinová and M. Petríková,Antiaggregatory properties of beta-adrenoceptor blocking drugs are related to their physico-chemical properties. Platelets3, 29–33 (1992).Google Scholar
- R. Nosál, M. Petríková and V. JančinováAlterations in lipid peroxidation of thrombin stimulated rat platelets treated with beta-adrenoceptor blocking drugs. J. Lipid Med.8, 121–132 (1993).Google Scholar